Harmony Biosciences Holdings (HRMY) Enterprise Value (2019 - 2026)

Harmony Biosciences Holdings has disclosed Enterprise Value across 8 years of filings, most recently posting -$640.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$640.9 million, down 45.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$640.9 million (down 45.22% YoY), and the FY2025 annual result was -$775.3 million, down 65.96% from the prior year.
• Enterprise Value came in at -$640.9 million for Q1 2026 at Harmony Biosciences Holdings, up from -$775.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$224.5 million in Q1 2022 to a low of -$775.3 million in Q4 2025.
• The 5-year median for Enterprise Value is -$372.3 million (2024), against an average of -$428.8 million.
• Across the five-year window, Enterprise Value plunged 133.58% in 2022 and increased 13.54% in 2024, its largest moves.
• Harmony Biosciences Holdings' Enterprise Value stood at -$366.2 million in 2022, then advanced by 3.48% to -$353.5 million in 2023, then slumped by 32.18% to -$467.2 million in 2024, then tumbled by 65.96% to -$775.3 million in 2025, then gained by 17.34% to -$640.9 million in 2026.
• The last three Enterprise Value figures came in at -$640.9 million (Q1 2026), -$775.3 million (Q4 2025), and -$672.6 million (Q3 2025), per Business Quant data.